Nilotinib Hydrochloride is Used for treating Philadelphia chromosome-positive chronic myeloid leukemia (PH+CML) with nilotinib dispersed in a fruit preparation. It was first introduced by Novartis Pharmaceuticals Corp in its drug Tasigna on Oct 29, 2007. 2 different companies have introduced drugs containing Nilotinib Hydrochloride.

Nilotinib Hydrochloride Patents

Given below is the list of patents protecting Nilotinib Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Tasigna	US7169791	Inhibitors of tyrosine kinases	Jul 04, 2023 (Expired)	Novartis
Tasigna	US7169791	Inhibitors of tyrosine kinases	Jul 04, 2023 (Expired)	Novartis
Tasigna	US7169791 (Pediatric)	Inhibitors of tyrosine kinases	Jan 04, 2024 (Expired)	Novartis
Tasigna	US8163904	Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide	Aug 23, 2028	Novartis
Tasigna	US8163904 (Pediatric)	Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide	Feb 23, 2029	Novartis
Tasigna	US8293756	Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate	Sep 25, 2027	Novartis
Tasigna	US8293756 (Pediatric)	Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate	Mar 25, 2028	Novartis
Tasigna	US8389537	Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide	Jul 18, 2026	Novartis
Tasigna	US8389537 (Pediatric)	Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide	Jan 18, 2027	Novartis
Tasigna	US8415363	Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide	Jul 18, 2026	Novartis
Tasigna	US8415363 (Pediatric)	Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide	Jan 18, 2027	Novartis
Tasigna	US8501760	Pharmaceutical compositions comprising nilotinib or its salt	Jul 18, 2026	Novartis
Tasigna	US8501760 (Pediatric)	Pharmaceutical compositions comprising nilotinib or its salt	Jan 18, 2027	Novartis
Tasigna	US9061029	Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity	Apr 07, 2032	Novartis
Tasigna	US9061029 (Pediatric)	Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity	Oct 07, 2032	Novartis

Add above patents to watchlist

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Nilotinib Hydrochloride's patents.

Latest Legal Activities on Nilotinib Hydrochloride's Patents

Given below is the list recent legal activities going on the following patents of Nilotinib Hydrochloride.

Event	Date	Patent/Publication
Critical Events This Week
Payment of Maintenance Fee, 12th Year, Large Entity	10 Apr, 2024	US8293756
Payment of Maintenance Fee, 12th Year, Large Entity	11 Oct, 2023	US8163904
Payment of Maintenance Fee, 8th Year, Large Entity	07 Dec, 2022	US9061029
Payment of Maintenance Fee, 8th Year, Large Entity	20 Jan, 2021	US8501760
Payment of Maintenance Fee, 8th Year, Large Entity	24 Sep, 2020	US8415363
Payment of Maintenance Fee, 8th Year, Large Entity	21 Aug, 2020	US8389537
Payment of Maintenance Fee, 8th Year, Large Entity	14 Apr, 2020	US8293756
Payment of Maintenance Fee, 8th Year, Large Entity	10 Oct, 2019	US8163904
Payment of Maintenance Fee, 4th Year, Large Entity	07 Dec, 2018	US9061029
Payment of Maintenance Fee, 12th Year, Large Entity	19 Jul, 2018	US7169791

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳